Responses
Abstracts from the Neonatal and Paediatric Pharmacists Conference November 2019
Sutton Coldfield, UK
P60 Efficacy of switching to infliximab biosimilar (Remsima®) in paediatric inflammatory bowel disease (PIBD): a 2-Year retrospective evaluation
Compose a Response to This Article
Other responses
No responses have been published for this article.